Nardostachys Jatamansi

1. What conditions has Nardostachys Jatamansi been studied for?

• Alzheimer’s disease (AD) / cognitive impairment: Studied for acetylcholinesterase (AChE) inhibition (a common AD drug target) and for neuroprotection against β-amyloid (Aβ) toxicity in cell and animal models (Drosophila AD model mentioned).

• Parkinson’s disease (PD): Studied in a rotenone-induced rat PD model, including combination therapy with levodopa, with mechanistic focus on Nrf2 and NLRP3 pathways.

• Depression / antidepressant activity: Studied in behavioral models (tail suspension test and open field test) and for effects on the serotonin transporter (SERT) using high-content assays.

• Inflammation and tissue remodeling (skin/cell models): N. jatamansi essential oil appears to be among essential oils tested in a “pre-inflamed human dermal fibroblast” system assessing inflammatory/immune/tissue remodeling proteins (abstract is truncated, so details are limited).

• Metabolic/cardiovascular enzyme targets (preclinical, in vitro): Extracts from different plant parts were tested for enzyme inhibition linked to hyperglycemia (α-amylase, PTP1B), hypertension (ACE), and other targets (tyrosinase), plus anti-inflammatory enzymes (5-lipoxygenase, hyaluronidase).

• Cancer cytotoxicity (in vitro): Rootstock extracts tested against cancer cell lines (HCT-116, MCF-7, OE33) and normal cell lines (HEK, MEF).

• Traditional/ethnomedical indications (not necessarily clinically tested): Insomnia, anxiety, epilepsy, hysteria, digestive and neuropsychiatric disorders are described in ethnopharmacology reviews and traditional medicine summaries.

2. Does it work in treating those conditions? Summarize the evidence.

• Alzheimer’s disease / cognition:

  • In vitro target-based evidence: A methanolic extract of N. jatamansi was among 5 of 20 Ayurvedic cognition-related plants with AChE inhibitory activity IC50 < 100 µg/mL (Ellman assay). This supports potential symptomatic relevance (cholinesterase inhibition), but does not demonstrate clinical benefit.

  • Preclinical neuroprotection: An ethanol extract of N. jatamansi root was tested for protection against Aβ toxicity in cell culture and a Drosophila AD model (mechanistic details and outcomes are not provided in the excerpt, so strength of evidence cannot be fully assessed from the study text shown).

  • Overall: Evidence is preclinical (enzyme assays and model systems). No human clinical trial outcomes are provided in the supplied studies.

• Parkinson’s disease:

  • Animal model evidence (combination therapy): In rotenone-induced PD rats, N. jatamansi (NJ) + levodopa improved locomotor activity versus model animals; the study reports increased open-field moving distance for the high-dose NJ + levodopa group compared with model (numerical values are given, but the excerpt is truncated before statistical details).

  • Mechanistic signals: The study investigated Nrf2 and NLRP3 pathway expression as potential mechanisms for synergy with levodopa.

  • Overall: Suggests potential adjunct benefit in an animal model; not evidence of efficacy in humans.

• Depression:

  • Behavioral model evidence: Total methanol extract showed antidepressant-like effects in tail suspension test (TST) and open field test (OFT).

  • Proposed mechanism: The study reports effects on SERT activity and describes a water-soluble fraction enriched with “SERT enhancing constituents,” presented as a novel type of natural SERT-enhancing extract/fraction.

  • Overall: Promising mechanistic and animal/behavioral data, but no clinical depression trials are provided.

• Other enzyme targets / anti-inflammatory / antioxidant:

  • In vitro evidence: Multiple extracts (wild and in vitro-raised plants; different parts/solvents) showed activity against AChE/BuChE and enzymes linked to hyperglycemia, hypertension, inflammation, and tyrosinase. These are screening-level findings and do not establish clinical efficacy.

  • Antioxidant: In the 20-plant screen, N. jatamansi was highlighted for AChE inhibition, while the strongest DPPH antioxidant activity was reported for other plants (Terminalia chebula, Emblica officinalis). This suggests N. jatamansi may not be the top antioxidant among those tested, at least in that assay set.

Key limitation across conditions: The supplied studies largely describe in vitro assays and animal models. A review abstract explicitly notes absence of toxicology studies using animal models and clinical trials using human subjects in much of the literature, plus concerns about sample authenticity (see downsides).

3. What health benefits does it have?

• Potential cognitive/AD-relevant benefits (preclinical):

  • AChE inhibition (IC50 < 100 µg/mL for methanolic extract in a screening study), which is a validated symptomatic target in AD drug therapy.

  • Neuroprotection against Aβ toxicity in cell culture and a Drosophila AD model (based on the study excerpt; details not shown).

• Potential adjunct support in PD (animal data):

  • In rotenone PD rats, NJ + levodopa improved locomotor outcomes compared with model animals, suggesting possible synergy.

  • Mechanistic association with Nrf2 (often linked to antioxidant/cytoprotective responses) and NLRP3 (inflammation-related) pathways was investigated.

• Potential antidepressant effects (preclinical):

  • Antidepressant-like effects in TST/OFT and modulation of SERT activity in assays, with a described water-soluble fraction enriched in SERT-enhancing constituents.

• Broad bioactivity signals (in vitro):

  • Reported anti-inflammatory enzyme inhibition (e.g., 5-lipoxygenase, hyaluronidase) and metabolic/cardiovascular enzyme inhibition (α-amylase, PTP1B, ACE) in extract testing.

  • Some studies report antioxidant activity and secondary metabolite richness, including comparisons of wild vs in vitro-raised plants.

Practical interpretation: The studies support N. jatamansi as a source of bioactive compounds with plausible CNS-relevant mechanisms (cholinesterase inhibition; SERT-related activity; neuroinflammation/oxidative-stress pathways), but they do not establish proven human health benefits.

4. Does it have any downsides or side effects?

• Evidence gaps in safety: A review abstract highlights limitations across the literature, including absence of toxicology studies (and absence of clinical trials) in many reports. This means side effects, safe dosing, and drug interactions are not well characterized from the provided evidence.

• Authentication/quality concerns (major downside for real-world use): The review notes “uncanny resemblance” between phytochemical profiles/activities of N. jatamansi and Valeriana jatamansi, possibly due to misidentification because they share vernacular names. This creates risk that products/studies may not involve the intended species, complicating both efficacy and safety conclusions.

• Potential for drug interaction (theoretical based on mechanisms studied):

  • With levodopa in PD: One animal study intentionally combined NJ with levodopa and found synergy. While potentially beneficial, it also implies NJ could alter levodopa response; human interaction risk is unknown from these studies.

  • Serotonergic effects: Because NJ extracts/fractions were studied for SERT-related activity, there is a plausible interaction concern with serotonergic drugs (e.g., SSRIs/SNRIs/MAOIs), but the studies do not provide clinical interaction or adverse event data.

  • Cholinesterase inhibition: AChE/BuChE inhibition suggests possible additive effects with cholinesterase-inhibiting drugs used in dementia, but again no clinical safety data are provided here.

• Conservation/ethical downside: The plant is described as critically endangered and threatened due to overexploitation and illegal trade of rhizomes. This is not a physiological side effect, but it is a significant downside for supplement sourcing and sustainability.

• Cytotoxicity signals (context-dependent): Extracts were tested for cytotoxicity against cancer and normal cell lines. Without results in the excerpt, this cannot be interpreted as either a benefit (anticancer potential) or a safety risk, but it underscores the need for dose-appropriate toxicology.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (e.g., effects by genotype, or interactions with specific genetic variants in drug-metabolizing enzymes/transporters or disease-risk genes).

• No direct evidence in these studies linking N. jatamansi response or safety to genetic variants.

• Mechanism-based hypotheses (not proven):

  • SERT-related effects: Because antidepressant activity was linked to SERT modulation, variants in SLC6A4 (SERT gene) could theoretically influence response, but this is not tested in the cited studies.

  • Nrf2 pathway: The PD synergy study examined Nrf2 signaling; variants in NFE2L2 (Nrf2) or related oxidative-stress genes could theoretically modify effects, but no genotype-stratified data are provided.

Bottom line: Pharmacogenomic benefit/harm is currently unknown based on the supplied studies; any claims would be speculative without human genotype-linked studies.

References

1. In vitro screening for anti-cholinesterase and antioxidant activity of methanolic extracts of ayurvedic medicinal plants used for cognitive disorders.
   Maya Mathew, Sarada Subramanian (2014) - PloS one
2. Nardostachys jatamansi (D.Don) DC.-Challenges and opportunities of harnessing the untapped medicinal plant from the Himalayas.
   Nisha Dhiman, Amita Bhattacharya (2020) - Journal of ethnopharmacology
3. Nardostachys jatamansi and levodopa combination alleviates Parkinson's disease symptoms in rats through activation of Nrf2 and inhibition of NLRP3 signaling pathways.
   Jiayuan Li, Jiahe Yu, Jianyou Guo, Jinfeng Liu, Guohui Wan, Xiaojia Wei, Xue Yang, Jinli Shi (2023) - Pharmaceutical biology
4. Antidepressant activities and regulative effects on serotonin transporter of Nardostachys jatamansi DC.
   Ran Li, Zhi-Mei Wang, Yan Wang, Xueqi Dong, Li-Hua Zhang, Tao Wang, Yan Zhu, Xiu-Mei Gao, Hong-Hua Wu, Yan-Tong Xu (2021) - Journal of ethnopharmacology
5. Secondary metabolite profiling, cytotoxicity, anti-inflammatory potential and in vitro inhibitory activities of Nardostachys jatamansi on key enzymes linked to hyperglycemia, hypertension and cognitive disorders.
   Biswajit Bose, Debabrata Tripathy, Anupam Chatterjee, Pramod Tandon, Suman Kumaria (2019) - Phytomedicine : international journal of phytotherapy and phytopharmacology
6. Ethnomedicinal uses of plants for the treatment of nervous disorders at the herbal markets of Bojnord, North Khorasan Province, Iran.
   Mohabat Nadaf, Mohammad Joharchi, Mohammad Sadegh Amiri (2019) - Avicenna journal of phytomedicine
7. Ethnopharmacological approach to the herbal medicines of the "Antidotes" in Nikolaos Myrepsos׳ Dynameron.
   E Valiakos, M Marselos, N Sakellaridis, Th Constantinidis, H Skaltsa (2015) - Journal of ethnopharmacology
8. The effects of Nardosinone on levodopa intervention in the treatment of Parkinson's disease.
   Mengmeng Liu, Jingwen Xue, Yuxin Cao, Zhuangzhuang Hao, Yuqing Wang, Jiayuan Li, Tingyue Jiang, Jinli Shi (2024) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
9. In vitro antioxidant and free radical scavenging activity of Nardostachys jatamansi DC.
   Surendra Kumar Sharma, Ajay Pal Singh (2012) - Journal of acupuncture and meridian studies
10. Protective effect of Nardostachys jatamansi extract against lithium-pilocarpine-induced spontaneous recurrent seizures and associated cardiac irregularities in a rat model.
    Supriya Sharma, Anil Kumar Rana, Shubham Nilkanth Rahmatkar, Vikram Patial, Damanpreet Singh (2023) - Journal of ethnopharmacology
11. Medicinal plants from the Himalayan region for potential novel antimicrobial and anti-inflammatory skin treatments.
    Michael Heinrich, Haiping Jiang, Francesca Scotti, Anthony Booker, Heinrich Walt, Caroline Weckerle, Caroline Maake (2021) - The Journal of pharmacy and pharmacology
12. Nardosinone Alleviates Parkinson's Disease Symptoms in Mice by Regulating Dopamine D2 Receptor.
    Li-Hua Bian, Zi-Wei Yao, Cheng-Bowen Zhao, Qiu-Yu Li, Jin-Li Shi, Jian-You Guo (2021) - Evidence-based complementary and alternative medicine : eCAM
13. A review of nardosinone for pharmacological activities.
    Jiawei Wen, Linqiu Liu, Junjun Li, Yang He (2021) - European journal of pharmacology
14. Aristolone in Nardostachys jatamansi DC. induces mesenteric vasodilation and ameliorates hypertension via activation of the K
    Jingmei Fang, Ran Li, Yue Zhang, Patrick Kwabena Oduro, Sa Li, Ling Leng, Zhimei Wang, Yao Rao, Lu Niu, Hong-Hua Wu, Qilong Wang (2022) - Phytomedicine : international journal of phytotherapy and phytopharmacology
15. Desoxo-narchinol A and Narchinol B Isolated from Nardostachys jatamansi Exert Anti-neuroinflammatory Effects by Up-regulating of Nuclear Transcription Factor Erythroid-2-Related Factor 2/Heme Oxygenase-1 Signaling.
    Kwan-Woo Kim, Chi-Su Yoon, Youn-Chul Kim, Hyuncheol Oh (2019) - Neurotoxicity research
16. Stability of valeriana-type iridoid glycosides from rhizomes of Nardostachys jatamansi and their protection against H
    Trung Huy Ngo, Ajay Uprety, Manju Ojha, Yun-Seo Kil, Hyukjae Choi, Soo Young Kim, Joo-Won Nam (2022) - Phytochemistry

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.